EN
English✓简体中文繁體中文TürkçeEspañolBahasa MelayuBahasa IndonesiaTiếng ViệtPortuguêsРусский

Only complete language versions are shown.

Let’s talk

Before Traveling to China for DLBCL Care: Confirm Acceptance, Treatment Timing, and Travel Requirements

EastMedGo

If you have diffuse large B-cell lymphoma (DLBCL) and are considering care in China, first ask your current hematologist what issue needs to be addressed, whether your condition can wait, and whether you are fit to travel. At the same time, ask the receiving team in China to confirm whether they can assess you, when they can see you, what records they expect to need, and how long you may need to stay. If timely treatment is available locally, you can also discuss whether a remote second opinion would be enough.

Key points

  • Aggressive lymphoma can progress quickly. Your current team must judge whether you can wait for a consultation or travel; do not stop medication or delay necessary treatment on your own.
  • An appointment response, treatment eligibility, drug availability, and final costs are separate matters. Confirm each with the receiving institution.
  • During chemotherapy, contact your treatment team immediately if your temperature reaches or exceeds 38°C. If you cannot reach them, go to the nearest emergency department as soon as possible. Follow your doctor's instructions if they tell you to seek help sooner.
  • Seek local help promptly for fever, signs of infection, or significant deterioration. Know who will arrange your next treatment if your trip is canceled.

Identify treatment that cannot wait

Bring your pathology report, staging information and imaging, recent laboratory results, and treatment timeline. Explain to your current hematologist what advice you hope to receive, such as a review of the diagnosis, an explanation of treatment response, or an assessment of options after relapse. Ask which decisions can wait, what tests or care you need while waiting, and who is responsible if your condition changes. A second opinion may confirm the original plan or raise questions that need further investigation.

If you only need a pathology review, first ask the intended receiving laboratory whether it can review reports, slides, or paraffin blocks before you travel, and what its transfer and shipping requirements are. The receiving team should decide, based on the materials, whether you must attend in person or need a new biopsy.

Decide whether travel is needed based on your current concern

Your local diagnosis is clear and treatment can begin promptly: You can first ask another hematologist for a second opinion on specific questions, comparing the pathology, staging, and physical condition considered by both doctors. A second opinion may also confirm your current plan. Obtaining an opinion and deciding whether to travel to China in person are separate decisions. Do not interrupt ongoing treatment on your own while waiting for a response from abroad.

Pathology findings differ or results are incomplete: First ask your original pathology department and the intended receiving laboratory whether they need the full report, slides, paraffin blocks, or other materials, and whether they can review them before you travel. Ask how long shipping and results are expected to take, and which questions still require an in-person visit or new samples. Ask your current hematologist to decide how you should be cared for while waiting. Shipping times must not determine whether treatment can begin.

Your lymphoma has relapsed or treatment has not worked as expected: Give the intended receiving team details of the drugs used in each line of treatment, dates, best response, time of progression, and serious side effects. Ask whether they can assess your current stage of treatment. The options that may be discussed depend on pathology, previous treatment, your physical condition, and local availability. Ask the team to explain which tests are still needed, who is responsible while you wait, and what alternatives are available if you cannot receive the proposed treatment.

Ask the receiving team to confirm exactly what they can offer

Ask the hospital in China whether it accepts patients with your condition, whether your records are sufficient, which department and appointment dates are available, whether you need on-site tests or an interpreter, and how to obtain a written opinion. If CAR-T or another complex treatment is being discussed, clarify whether an individual assessment is currently available, the possible waiting and observation arrangements, and who will manage your condition during that time. A hospital offering a treatment does not mean you are already eligible for it.

Plan treatment and travel on the same schedule

Review the next treatment dose, laboratory tests, response assessment, possible monitoring for low blood cell counts, and emergency arrangements with doctors in both countries. Clarify what the team in China and the team in your home country will each be responsible for. Ask how long you need to stay in China, who decides whether you can return home, and how plans will be changed if flights are delayed or test results are abnormal. Whether you can travel back and forth during treatment depends on your individual condition; do not book flights based only on infusion dates.

Check prescriptions, drug supplies, storage requirements, and rules for carrying medicines throughout your journey. Ask the hospital to estimate consultation, drug, administration, testing, bed, and supportive care costs separately, and to state which items are unconfirmed or may cost extra. List accommodation, companion, interpreting, transport, and rebooking costs separately, and confirm actual coverage with your insurer. When choosing accommodation, consider more than distance: confirm transport to the treatment site and emergency care at night, and whether your companion can help with communication and daily care.

Before departure, contact a hematology team that can take over after you return home. Confirm whether it can continue to obtain your medicines, perform blood counts or imaging, and manage abnormal findings. The team in China needs to provide pathology and imaging records, a treatment summary, actual doses and dates, side effects, and the next follow-up plan. If continuity of care cannot be arranged, ask the teams in both countries to discuss alternatives.

Plan for the full course of complex treatment

If CAR-T is being discussed, ask the center to explain which institution will handle each stage: records review, individual eligibility assessment, cell collection, the wait for manufacturing, any bridging treatment needed during the wait, infusion, and observation. Clarify how your condition will be managed while waiting, whether a caregiver needs to stay nearby, what might change the schedule, and when the original treatment center will reassess whether you can return home. Completing cell collection or infusion does not mean follow-up monitoring is finished. The actual center must confirm the specific product, indication, availability, and required length of stay.

Before leaving the hospital after infusion, ask the treatment center to give you a personal written monitoring and emergency plan: which symptoms to watch for, where to have tests, and when to return for follow-up; how to seek help for fever, chills, or changes in awareness or speech; the center's daytime and nighttime contact numbers; arrangements for going to the nearest emergency department if the center cannot be reached; and when you will be reassessed before returning home. Confirm with both teams who will take over monitoring and management of problems during flight connections and after you return home. Carry the product name, infusion date, and any alert card or written information provided by the center. The treatment center determines the observation period, when to seek help, and the conditions for returning home based on the specific product and your individual situation.

If bispecific antibodies are being discussed, ask which drug is proposed, whether initial doses are given in steps, which doses require observation or hospitalization, and where later doses and tests will take place. Ask the treatment center to provide a personal written emergency plan and daytime and nighttime contacts for fever, chills, dizziness, or changes in awareness or speech. When seeking medical care, give the drug name and the date of your most recent dose. Arrangements vary by product and individual. A US product label or study does not establish that the same drug is currently approved or available in China, or suitable for you. If dosing or monitoring cannot continue after you return home, have doctors in both countries agree on a complete care plan before treatment begins.

For clinical trials, ask not only for the registration number and screening criteria, but also whether the actual center is recruiting, the expected number of visits, required tests or medication interruptions, which items the study pays for and which you must pay for, and who will arrange care if you do not pass screening or withdraw. Ask the research team to explain informed consent, group assignment if applicable, how study-related harm is handled, and who is responsible for costs. Any change to your current medicines must be coordinated between your current doctor and the research team. Do not stop medicines on your own to meet eligibility criteria.

Recheck fitness to fly and emergency arrangements before departure

Ask your treating doctor to assess your recent condition, blood counts, infection status, physical stamina, need for oxygen or a companion, and whether the proposed itinerary is suitable. Confirm medical documentation and special assistance requirements with the airline operating your flights. Plans may need to change as your condition or the hospital's ability to receive you changes.

During chemotherapy, take your temperature if you feel feverish, chilled, or unwell. If your temperature reaches or exceeds 38°C during chemotherapy, contact your local treatment team immediately and seek care according to their emergency instructions. Follow your doctor's instructions if they tell you to seek help sooner. If you develop a fever, contact the team immediately even if you have not yet been given a personal temperature threshold. If you cannot reach them promptly, go to the nearest emergency department as soon as possible and explain that you have DLBCL and have recently received treatment. Fever during other treatment stages also requires immediate contact with the team; if they cannot be reached, go to the nearest emergency department as soon as possible. Do not treat the chemotherapy reference temperature as a universal threshold for all treatments.

Contact the team promptly for signs of infection such as chills, cough, diarrhea, pain when urinating, or redness and swelling around a catheter, even without fever. If you cannot reach them promptly, seek assessment at a local medical facility as soon as possible. Also contact the team promptly for persistent or repeated bleeding, blood in the urine, black stools, or new unusual bruising. If you cannot reach them promptly, seek local assessment as soon as possible.

For severe difficulty breathing, altered consciousness, or heavy bleeding, call local emergency services immediately. For new or rapidly worsening limb weakness, difficulty walking, numbness, or changes in bladder or bowel function, go to a local emergency department or call local emergency services immediately, even without back pain. These symptoms can have several causes; do not try to determine the cause yourself.

After recent CAR-T or bispecific antibody treatment, new confusion, marked drowsiness, difficulty speaking, or seizures require immediate care at a local emergency department or a call to local emergency services. Do not wait for a reply from another country. Tell medical staff the specific product or drug and the date of your most recent infusion or dose. Carry any alert card or written information provided by the treatment center, if available, but do not delay seeking help to find these materials.

Before departure, write down how to seek help at your departure point, connection points, and destination. Agree with your treatment team who will take over necessary care if you develop a fever or cannot board your flight.

Frequently asked questions

Can I seek a second opinion if I have already started treatment locally?

First discuss continuity of care with your treating team, and provide pretreatment pathology and imaging, treatment dates, and responses. Whether travel is needed depends on the assessment findings and your physical condition.

Can I get an opinion by sending only pathology materials?

Some questions may be addressed initially through a records or specimen review, but the receiving team must decide whether the materials are sufficient. First ask for specific requirements for reports, slides, or paraffin blocks and how to send them.

If a hospital says it offers CAR-T, does that mean I can receive it?

You cannot assume this. You need to understand the specific assessment, treatment timing, waiting period, and follow-up monitoring, and the team must assess your individual situation.

How long do I need to stay in China for CAR-T or bispecific antibody treatment?

There is no single duration that suits everyone. Ask the center to explain when it will reassess whether you can return home, based on the specific product and the assessment, treatment, and observation stages. Allow for the possibility of a longer stay and extended caregiver support.

If a trial registry says “recruiting,” can I enroll directly?

No. Confirm the cohort and screening requirements with the actual center. Meeting preliminary criteria does not mean you are formally enrolled.

What if my local doctor and the doctor in China give different advice?

Ask both to explain the materials they reviewed, where they disagree, and what additional evidence is needed. Confirm who is responsible for your treatment in the immediate future. Have urgent symptoms treated locally first.

If I feel well, can I decide for myself whether to fly?

First ask your doctor to assess your condition and itinerary, then confirm the airline's specific requirements. Symptoms, blood counts, and monitoring needs after treatment can all affect arrangements.

If I develop a fever before departure, should I take fever medicine and continue to the airport?

Do not delay assessment to keep to your itinerary. Contact your local team immediately. If you cannot reach them promptly, go to the nearest emergency department as soon as possible. Your doctor should decide whether you should take fever medicine and when you can travel.

Sources

Chat on WhatsAppEmail